SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Stock Picking for Charity - 2006

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DNA-Jock who wrote (409)6/6/2006 10:39:24 AM
From: dr.praveen  Read Replies (1) of 592
 
acusphere.com

Market seems to totally disagree. Hit my stop limits and my shares were sold off too. My mind can't seem to agree..

From the CC:

on the sensitivity issue,there might be a trade off between sensitivity and specificity. The reader who was most specific was also the most conservative in that he didn't call borderline abnormalities as much as the guy who was more sensitive. If you Call borderline abns it makes the test more sensitive but less specific.So it's open for shades of grey in interpretation.

The RAMP II will include more number of readers and as the no of readers increases there might be a better effect of inter reader variability on the sen/spec issue. Might be in RAMP II,
when AI700 is compared to the gold standard coronory artery cath, results might be better.

Hmmm...666 effect:-( :-) ?
Praveen
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext